Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMXT 1501 and DFMO for Relapsed/Refractory Neuroblastoma, CNS Tumors, and Sarcomas
NCT06465199Phase 2Recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- May 2026
- Primary completion
- May 2033
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AMXT-1501 in neuroblastoma, Atypical teratoid rhabdoid tumor (ATRT), embryonal tumor with multilayered rosettes (ETMR), Ewing sarcoma, diffuse intrinsic pontine glioma (DIPG), sponsored by Penn State Health Milton S. Hershey Medical Center. Started May 2026; status: recruiting.
02
Drugs
AMXT-1501
03
Conditions
neuroblastomaAtypical teratoid rhabdoid tumor (ATRT)embryonal tumor with multilayered rosettes (ETMR)Ewing sarcomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT06465199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465199.